Patents involving antibody medicines (antibody patents) are largely grouped into patents specified by antibody amino acid sequences (antibody sequence-based patents) and those not (non-sequence-based patents). Non-sequence-based patents have a broad scope and are thus very useful for protecting antibody medicines. Here, I investigate a recent trend in antibody patents characterized by an antibody-binding site in an antigen.
Case Study: Recently Granted Epitope-Based Antibody Patents in the United States, Europe and Japan
No Comments
Patent
- Enablement
- Fee Shifting
- Litigation
- AAM v. Neapco Comes Full Circle: The Foundation of Invention Becomes its Trap (Part II)
- Senate IP Subcommittee Continues Search for Balance on Potential Copyright Reforms
- Gathering Business Data? Be Careful, Mom is Watching – A Comment on Data Scraping and the Compulife Case
- Recent Trademark Developments: Four Cases Shaping the Law in the United States and Beyond
- Other Barks & Bites for Friday, September 18: USPTO Announces COVID-19 Provisional Patent Pilot, Copyright Office Issues MMA Ruling and China Issues Draft Patent Linkage Measures
Recent Posts
- Japan: Supreme Court Says Retweeting Tweet with Photo Infringes Right of Attribution
- AAM v. Neapco Comes Full Circle: The Foundation of Invention Becomes its Trap (Part II)
- Senate IP Subcommittee Continues Search for Balance on Potential Copyright Reforms
- Gathering Business Data? Be Careful, Mom is Watching – A Comment on Data Scraping and the Compulife Case
- Recent Trademark Developments: Four Cases Shaping the Law in the United States and Beyond